Product image of Linezolid Accord (Linezolid) supplied by GNH India

Linezolid Accord

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Accord (Linezolid)

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as a intravenous formulation for intravenous use. It treats Gram‑positive bacterial infections including MRSA, skin and soft‑tissue infections, and community‑acquired or nosocomial pneumonia in adult patients.

GNH India supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linezolid Accord is indicated for infections caused by Gram‑positive bacteria, targeting the pathways of protein synthesis inhibition.

  • Skin and soft tissue infections: effective against Staphylococcus aureus and Streptococcus species, reducing infection severity.
  • Community‑acquired and nosocomial pneumonia: provides bacterial clearance in lung infections caused by susceptible Gram‑positive organisms.
  • Methicillin‑resistant Staphylococcus aureus (MRSA) infections: achieves bacteriostatic activity against resistant strains.

How It Works

  • Linezolid binds to the 50S ribosomal subunit of susceptible bacteria, preventing formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth, leading to a bacteriostatic effect against Gram‑positive organisms, including strains resistant to other antibiotic classes.

Side Effects

Adverse reactions may occur with linezolid therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, occasionally watery.
  • Headache: transient cranial discomfort.
  • Vomiting: occasional emesis.
  • Rash: mild skin erythema.
  • Metallic taste: altered taste perception.

Serious or Rare Side Effects

  • Thrombocytopenia: significant drop in platelet count.
  • Anemia: reduced red blood cell levels.
  • Peripheral neuropathy: nerve pain or sensory changes.
  • Serotonin syndrome: risk when combined with serotonergic agents.
  • Lactic acidosis: metabolic disturbance.
  • Optic neuritis: visual disturbances requiring immediate attention.

Precautions & Warnings

Clinicians should consider several safety measures before initiating linezolid therapy.

  • Renal impairment: monitor renal function and adjust monitoring as linezolid is primarily excreted unchanged.
  • Hepatic dysfunction: assess liver enzymes regularly.
  • Concomitant serotonergic agents: avoid due to risk of serotonin syndrome.
  • Myelosuppression: perform routine complete blood counts.
  • Hypersensitivity: discontinue immediately if allergic reaction occurs.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Linezolid may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome.
  • Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome.
  • Rifampicin: reduces linezolid plasma concentrations.
  • Erythromycin: may increase linezolid levels.
  • Tyramine‑rich foods: may precipitate hypertensive reactions.

Moderate Interactions (Monitor Closely)

  • Warfarin: may enhance anticoagulant effect.
  • Phenytoin: may lower linezolid concentrations.
  • Cimetidine: may increase linezolid exposure.
  • Anticonvulsants: monitor for reduced seizure control.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for bleeding risk.

Frequently Asked Questions

Linezolid Accord is an intravenous antibiotic indicated for the treatment of serious Gram‑positive bacterial infections, including skin and soft‑tissue infections, community‑acquired or nosocomial pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA).

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This action stops bacterial growth, providing a bacteriostatic effect against susceptible Gram‑positive organisms.

The dosage and duration of linezolid therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here.

Safety data for linezolid in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with vancomycin, another common Gram‑positive agent, linezolid offers oral and intravenous options, does not require therapeutic drug monitoring, and retains activity against many vancomycin‑resistant strains. However, vancomycin may be preferred for certain severe infections due to its bactericidal nature.

Linezolid Accord should be stored at ambient temperature, protected from moisture and light, and kept in its original packaging until use. Do not freeze the product, and ensure the vial is inspected for particulate matter before preparation.

The product is supplied for intravenous infusion. It is reconstituted with the appropriate diluent and administered over a recommended infusion period, typically 30 to 60 minutes, under aseptic conditions as directed by the healthcare professional.

Serious adverse events include thrombocytopenia, anemia, peripheral neuropathy, serotonin syndrome when combined with serotonergic drugs, lactic acidosis, and optic neuritis. Patients should be monitored regularly for hematologic changes and neurological symptoms.

Linezolid is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. Caution is advised for individuals taking serotonergic agents, MAO inhibitors, or those with pre‑existing severe myelosuppression.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linezolid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT